Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 5/2006

01-03-2006 | Review

Paraneoplastic rheumatic syndromes

Authors: Csilla András, Zoltán Csiki, Andrea Ponyi, Árpád Illés, Katalin Dankó

Published in: Rheumatology International | Issue 5/2006

Login to get access

Abstract

Paraneoplastic symptoms caused by a malignancy but not directly related to tumour invasion are the result of a wide variety of tumour-derived biologic mediators, such as hormones, peptides, antibodies, cytotoxic lymphocytes, autocrine and paracrine mediators. Recognition of paraneoplastic syndromes is important, as it may lead to an early diagnosis of cancer. On the other hand, the clinical severity of the symptoms can be used as a guide to the extent of response to underlying tumour therapy. The quality of life of the patient is affected, therefore the palliative treatment of paraneoplasia is very important.
Literature
1.
Chakravarty E, Genovese MC (2003) Rheumatic syndromes associated with malignancy. Curr Opin Rheumatol 15:35–43PubMedCrossRef
2.
3.
Marmur R, Kagen L (2002) Cancer-associated neuromusculoskeletal syndromes. Postgraduate Medicine: cancer-associated syndromes 111:95–102
4.
Kippel JH, Dieppe PA (1998) Rheumatology. Uncommon arthropathies; Zvaifler NJ. Cancer and miscellaneous arthropathies. Mosby, London 28.1–28.6
5.
Koopman WJ (2001) Arthritis and allied conditions. A textbook of rheumatology. Lippincott Williams and Wilkins, Canoso JJ: Tumors of joints and related structures; Nonmetastatic (Paraneoplastic) syndromes, pp 2088–2094
6.
Schwarzer AC, Schrieber L (1991) Rheumatic manifestations of neoplasia. Curr Opin Rheumatol 3:145–154PubMedCrossRef
7.
Martorell EA, Murray PM, Peterson JJ, Menke DM, Calamia KT (2004) Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg 29A:654–660
8.
Ruddy SC, Harris ED, Sledge CB (2001) Kelly’s textbook of rheumatology, vol 2. Paraneoplastic syndromes, pp 1606–1610
9.
Stertz G (1916) Polymyositis. Berl Klin Wochenshr 53:489
10.
11.
Yazici Y, Kagen LJ (2000) The association of malignancy with myositis. Curr Opin Rheumatol 12:498–500PubMedCrossRef
12.
Lakhanpal S, Bunch TW, Ilstrap DM, Melton LJ (1986) Polymyositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc 61:645–653PubMed
13.
Lyon MG, Bloch DA, Hollak B, Fries JF (1989) Predisposing factors in polymyositis-dermatomyositis: results of a nation-wide survey. J Rheumatol 16:1218–1224PubMed
14.
Manchul LA, Jin A, Pritchard KI, Tenenbaum J, Boyd NF, Lee P (1985) The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study. Arch Intern Med 145:1835–1839PubMedCrossRef
15.
Zantos D, Zhang Y, Felson D (1994) The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 21:1855–1859PubMed
16.
Stockton D, Doherty VR, Brewster DH (2001) Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 85:41–45PubMedCrossRef
17.
Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357:96–100PubMedCrossRef
18.
Buchbinder R, Forbes A, Hall S, Dennett X, Giles G (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 134:1087–1095PubMed
19.
Whitmore SE, Rosenshein NB, Provost TT (1994) Ovarian cancer in patients with dermatomyositis. Medicine 73:153–160PubMedCrossRef
20.
Callen JP (1994) Relationship of cancer to inflammatory muscle disease. Dermatomyositis, polymyositis and inclusion body myositis. Rheum Dis Clin North Am 20:943–953PubMed
21.
Rider LG, Miller FW (1997) Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 23:619–655PubMedCrossRef
22.
Whitmore SE, Watson R, Rosenshein NB, Provost TT (1996) Dermatomyositis sine myositis: association with malignancy. J Rheumatol 23:101–105PubMed
23.
Airio A, Pukkala E, Isomaki H (1995) Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 22:1300–1303PubMed
24.
Fujita J, Tokuda M, Bandoh S, Yang Y, Fukunaga Y, Hojo S (2001) Primary lung cancer associated with polymyositis/dermatomyositis, with a review of the literature. Rheumatol Int 20:81–84PubMedCrossRef
25.
Ang P, Sugeng MW, Chua SH (2000) Classical and amyopathic dermatomyositis seen at the National Skin Centre of Singapore: a 3-year retrospective review of their clinical characteristics and association with malignancy. Ann Acad Med Singapore 29:219–223PubMed
26.
Peng JC, Sheen TS, Hsu MM (1995) Nasopharyngeal carcinoma with dermatomyositis. Analysis of 12 cases. Arch Otolaryngol Head Neck Surg 121:1298–1301PubMed
27.
Rider LG, Miller FW (2000) Inflammatory muscle disease: clinical aspects. Baillière’s Clin Rheum 14:37–54
28.
Gallais V, Crickx B, Belaich S (1996) Prognostic factors and predictive signs of malignancy in adult dermatomyositis. Ann Dermatol Venereol 123:722–726PubMed
29.
Basset-Seguin N, Roujeau JC, Gherardi R, Guillaume JC, Revuz J, Touraine R (1990) Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases. Arch Dermatol 126:633–637PubMedCrossRef
30.
Hunger RE, Durr C, Brand CU (2001) Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology 202:123–126PubMedCrossRef
31.
Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas MC, Plotz PH (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogenous patient group. Medicine 70:360–374PubMedCrossRef
32.
Freundlich B, Makover D, Maul GG, Novel A (1988) Antinuclear antibody associated with a lupus-like paraneoplastic syndrome. Ann Intern Med 109:295–297PubMed
33.
Leandro MJ, Alsenberg D (2001) Rheumatic diseases and malignancy—is there an association? Scand J Rheumatol 30:185–188PubMedCrossRef
34.
Mok CC, Kwan YK (2003) Rheumatoid-like polyarthritis as a presenting feature of metastatic carcinoma: a case presentation and review of the literature. Clin Rheumatol 22:353–354PubMedCrossRef
35.
Glinkov S, Krasnaliev I, Atanassova M, Arnaudov P, Kirov K, Glinkova V (2003) Hepatocellular carcinoma associated with paraneoplastic erythema nodosum and polyarthritis. J Hepatol 39:656–657PubMedCrossRef
36.
Hamidou MA, Derenne M, Audrain MAP, Berthelot JM, Boumalassa A, Grolleau JY (2000) Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. Rheumatology 39:417–420PubMedCrossRef
37.
38.
Devita VT, Hellmann S, Rosenberg SA.(1993) Cancer. Principles and practice of oncology. Paraneoplastic syndromes, pp 2189–2211
39.
Shih WH (2004) Pulmonary hypertrophic osteoarthropathy and its resolution. Semin Nucl Med 34:159–163PubMedCrossRef
40.
Abe Y, Kurita S, Ohkubo Y, Usui H, Hashizume J, Nakamura M, Ueyama Y, Fujino T (2002) A case of pulmonary adenocarcinoma associated with hypertrophic osteoarthropathy due to vascular endothelial growth factor. Anticancer Res, pp 3485–3488
41.
Olán F, Portela M, Navarro C, Gaxiola M, Silveira LH, Ruiz V, Martínez-Lavín M (2004) Circulating vascular endothelial growth factor concentrations in a case of pulmonary hypertrophic osteoarthropathy. J Rheumatol 31:3
42.
Hall R, Hopkinson N, Hamblin T (2000) Relapsing polychondritis, smouldering non-secretory myeloma and early myelodysplastic syndrome in the same patient: three difficult diagnoses produce a life threatening illness. Leuk Res 24:91–93PubMedCrossRef
43.
Denschlag D, Riener E, Vaith P, Tempfer C, Keck C (2004) Palmar fasciitis and polyarthritis as a paraneoplastic syndrome associated with tubal carcinoma: a case report. Ann Rheum Dis 63:1177–1178PubMedCrossRef
44.
Docquier CH, Majois F, Mitine C, (2002) Palmar fasciitis and arthritis: association with endometrial adenocarcinoma. Clin Rheumatol 21:63–65PubMedCrossRef
45.
Enomoto M, Takemura H, Suzuki M, Yuhara T, Akama T, Sumida KYT (2000) Palmar fasciitis and polyarthritis associated with gastric carcinoma: complete resolution after total gastrectomy. Intern Med 39:9CrossRef
46.
Jakob SE, Lodha R, Cohen JJ, Romanelli P, Kirsner RS, (2003) Paraneoplastic eosinophilic fasciitis: a case report. Rheumatol Int 23:262–264CrossRef
47.
Preiss JC, Faiss S, Loddenkemper C, Zeitz M, Duchmann R (2002) Pancreatic panniculitis in an 88-Year-old man with neuroendocrine carcinoma. Digestion 66:193–196PubMedCrossRef
48.
Cox NH, Ramsay B, Dobson C, Comaish JS (1996) Woody hands in a patient with pancreatic carcinoma: a variant of cancer-associated fasciitis-panniculitis syndrome. Br J Dermatol 135:995–998PubMedCrossRef
49.
Maier C, Baron R, Loose R, Schröder D (1994) Endoskopische transthorakale Sympathektomie bei paraneoplastischem Raynaud-Syndrom. DMW 119:34–35
Metadata
Title
Paraneoplastic rheumatic syndromes
Authors
Csilla András
Zoltán Csiki
Andrea Ponyi
Árpád Illés
Katalin Dankó
Publication date
01-03-2006
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 5/2006
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-005-0005-3

Other articles of this Issue 5/2006

Rheumatology International 5/2006 Go to the issue

Original Article

Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes in vitro

Original Article

Determination of inflammation of reflex sympathetic dystrophy at early stages with Tc-99m HIG scintigraphy: preliminary results

Case Report

Nocardiosis in a patient with primary anti-phospholipid syndrome

Original Article

Prevalence of antibodies against oxidised LDL in a cohort of 163 patients with positive anti-phospholipid antibodies and recent thrombosis

Original Article

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

Case Report

Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits